Advertisement.
Advertisement.
Advertisement
Advertisement.
HROW Harrow Health Inc
2,271
| Market Cap | $857.3M |
| Volume | 231,051.00 |
| 52-Wk High | $25.58 |
| 52-Wk Low | $7.60 |
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
Business Wire•2 days ago
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August 7...
Share to Feed
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual...
Business Wire•15 days ago
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, it has entered into an agreement with Apexus to make IHEEZO (chloroprocaine...
Business Wire•18 days ago
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufacture of the first of three commercial-scale process performance...
Business Wire•1 month ago
Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3...
Business Wire•2 months ago
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE2 open-label extension (OLE) clinical study for VEVYE (cyclosporine...
Business Wire•2 months ago
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities...
Business Wire•2 months ago
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024. The Company also posted its first quarter Letter to...
Business Wire•2 months ago
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately...
Business Wire•2 months ago
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024...
Business Wire•3 months ago